Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 441

1.

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.

Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY.

Neuro Oncol. 2020 Jan 24. pii: noaa015. doi: 10.1093/neuonc/noaa015. [Epub ahead of print]

PMID:
31974566
2.

First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.

Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J.

Clin Cancer Res. 2020 Jan 14. pii: clincanres.2808.2019. doi: 10.1158/1078-0432.CCR-19-2808. [Epub ahead of print]

PMID:
31937616
3.

Large Collective Lamb Shift of Two Distant Superconducting Artificial Atoms.

Wen PY, Lin KT, Kockum AF, Suri B, Ian H, Chen JC, Mao SY, Chiu CC, Delsing P, Nori F, Lin GD, Hoi IC.

Phys Rev Lett. 2019 Dec 6;123(23):233602. doi: 10.1103/PhysRevLett.123.233602.

PMID:
31868475
4.

Towards a standard pathological and molecular characterization of recurrent glioma in adults: a RANO effort.

Haider AS, van den Bent M, Wen PY, Vogelbaum MA, Chang S, Canoll PD, Horbinski CM, Huse JT.

Neuro Oncol. 2019 Dec 17. pii: noz233. doi: 10.1093/neuonc/noz233. [Epub ahead of print]

PMID:
31844891
5.

A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).

Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Shmueli SF; GLOBE Study Investigators, Wen PY.

Neuro Oncol. 2019 Dec 17. pii: noz232. doi: 10.1093/neuonc/noz232. [Epub ahead of print]

PMID:
31844890
6.

Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study.

Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, Cloughesy TF, Sher N, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Yakov N, Mendel I, Breitbart E, Wen PY.

Neuro Oncol. 2019 Dec 17. pii: noz231. doi: 10.1093/neuonc/noz231. [Epub ahead of print]

PMID:
31844886
7.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, Lassman AB, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Cheng Y, Vicente S, Balbin OA, Zhang H, Wick W.

J Neurooncol. 2020 Jan;146(1):79-89. doi: 10.1007/s11060-019-03337-2. Epub 2019 Nov 27.

8.

Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification.

Ly KI, Wen PY, Huang RY.

Neurol Clin. 2020 Feb;38(1):95-113. doi: 10.1016/j.ncl.2019.08.004. Epub 2019 Nov 7. Review.

PMID:
31761063
9.

Glioma progression through synaptic activity.

Lim-Fat MJ, Wen PY.

Nat Rev Neurol. 2020 Jan;16(1):6-7. doi: 10.1038/s41582-019-0290-1. No abstract available.

PMID:
31745299
10.

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.

Arrillaga-Romany I, Odia Y, Prabhu VV, Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M, Batchelor TT, Wen PY.

Neuro Oncol. 2020 Jan 11;22(1):94-102. doi: 10.1093/neuonc/noz164.

PMID:
31702782
11.

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP.

J Neurooncol. 2019 Oct;145(1):97-105. doi: 10.1007/s11060-019-03271-3. Epub 2019 Aug 27.

PMID:
31456142
12.

Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.

Lee EQ, Muzikansky A, Duda DG, Gaffey S, Dietrich J, Nayak L, Chukwueke UN, Beroukhim R, Doherty L, Laub CK, LaFrankie D, Fontana B, Stefanik J, Ruland S, Caruso V, Bruno J, Ligon K, Reardon DA, Wen PY.

Cancer Med. 2019 Oct;8(13):5988-5994. doi: 10.1002/cam4.2505. Epub 2019 Aug 24.

13.

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.

Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D.

Cancer Res. 2019 Oct 1;79(19):5088-5101. doi: 10.1158/0008-5472.CAN-19-0325. Epub 2019 Aug 15.

PMID:
31416846
14.

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.

Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O'Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS.

Clin Cancer Res. 2019 Oct 1;25(19):5799-5807. doi: 10.1158/1078-0432.CCR-19-0261. Epub 2019 Jul 18.

PMID:
31320597
15.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Stupp R, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Dec 17;21(12):1498-1508. doi: 10.1093/neuonc/noz119.

PMID:
31276167
16.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186. No abstract available.

PMID:
31215634
17.

Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement.

Chang K, Beers AL, Bai HX, Brown JM, Ly KI, Li X, Senders JT, Kavouridis VK, Boaro A, Su C, Bi WL, Rapalino O, Liao W, Shen Q, Zhou H, Xiao B, Wang Y, Zhang PJ, Pinho MC, Wen PY, Batchelor TT, Boxerman JL, Arnaout O, Rosen BR, Gerstner ER, Yang L, Huang RY, Kalpathy-Cramer J.

Neuro Oncol. 2019 Nov 4;21(11):1412-1422. doi: 10.1093/neuonc/noz106.

18.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

PMID:
31175826
19.

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.

Ventz S, Lai A, Cloughesy TF, Wen PY, Trippa L, Alexander BM.

Clin Cancer Res. 2019 Aug 15;25(16):4993-5001. doi: 10.1158/1078-0432.CCR-19-0820. Epub 2019 Jun 7.

PMID:
31175098
20.

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.

Vanderbeek AM, Ventz S, Rahman R, Fell G, Cloughesy TF, Wen PY, Trippa L, Alexander BM.

Neuro Oncol. 2019 Oct 9;21(10):1239-1249. doi: 10.1093/neuonc/noz097.

PMID:
31155679
21.

Thrombotic Complications in Gliomas.

Czap AL, Becker A, Wen PY.

Semin Thromb Hemost. 2019 Jun;45(4):326-333. doi: 10.1055/s-0039-1687892. Epub 2019 Apr 30. Review.

PMID:
31041798
22.

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.

Fan B, Mellinghoff IK, Wen PY, Lowery MA, Goyal L, Tap WD, Pandya SS, Manyak E, Jiang L, Liu G, Nimkar T, Gliser C, Prahl Judge M, Agresta S, Yang H, Dai D.

Invest New Drugs. 2019 Apr 26. doi: 10.1007/s10637-019-00771-x. [Epub ahead of print]

PMID:
31028664
23.

[The status quo of amphetamine type stimulants use among residents aged 15-64 in a border city of Yunnan province, 2014].

Zhang CM, Luo J, Duan L, Yang GG, Li S, Wen PY, Li JH.

Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Apr 10;40(4):446-450. doi: 10.3760/cma.j.issn.0254-6450.2019.04.014. Chinese.

PMID:
31006206
24.

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium.

Seano G, Nia HT, Emblem KE, Datta M, Ren J, Krishnan S, Kloepper J, Pinho MC, Ho WW, Ghosh M, Askoxylakis V, Ferraro GB, Riedemann L, Gerstner ER, Batchelor TT, Wen PY, Lin NU, Grodzinsky AJ, Fukumura D, Huang P, Baish JW, Padera TP, Munn LL, Jain RK.

Nat Biomed Eng. 2019 Mar;3(3):230-245. doi: 10.1038/s41551-018-0334-7. Epub 2019 Jan 7.

25.

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.

Chukwueke UN, Wen PY.

CNS Oncol. 2019 Mar 1;8(1):CNS28. doi: 10.2217/cns-2018-0007. Epub 2019 Feb 26. Review. No abstract available.

26.

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.

Dunn IF, Du Z, Touat M, Sisti MB, Wen PY, Umeton R, Dubuc AM, Ducar M, Canoll PD, Severson E, Elvin JA, Ramkissoon SH, Lin JR, Cabrera L, Acevedo B, Sorger PK, Ligon KL, Santagata S, Reardon DA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00190. Epub 2018 Nov 27. No abstract available.

27.

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.

Schiff D, Van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY.

Neuro Oncol. 2019 Jul 11;21(7):837-853. doi: 10.1093/neuonc/noz033.

PMID:
30753579
28.

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM.

Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.

29.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

30.

Local control after brain-directed radiation in patients with cystic versus solid brain metastases.

Brigell RH, Cagney DN, Martin AM, Besse LA, Catalano PJ, Lee EQ, Wen PY, Brown PD, Phillips JG, Pashtan IM, Tanguturi SK, Haas-Kogan DA, Alexander BM, Aizer AA.

J Neurooncol. 2019 Apr;142(2):355-363. doi: 10.1007/s11060-019-03106-1. Epub 2019 Feb 4.

PMID:
30715665
31.

A low percentage of metastases in deep brain and temporal lobe structures.

Yanagihara TK, McFaline-Figueroa JR, Giacalone NJ, Lee AW, Soni V, Hwang ME, Hsieh KT, Saraf A, Wu CC, Yang D, Wen PY, Ashamalla H, Aizer AA, Wang TJC, Huang RY.

Neuro Oncol. 2019 May 6;21(5):640-647. doi: 10.1093/neuonc/noz023.

PMID:
30715520
32.

The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal.

Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, Hempel JM, Postma TJ, Roth P, Snijders TJ, Winkler F, Winklhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, Van den Bent M, Wen PY, Bendszus M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) Central Nervous System (CNS) Metastases Committee and the EORTC BTG Imaging Committee.

Neuro Oncol. 2019 May 6;21(5):648-658. doi: 10.1093/neuonc/noz024.

PMID:
30715514
33.

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.

Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, Glantz M, Groves MD, Lee EQ, Lin N, Raizer J, Rudà R, Weller M, Van den Bent MJ, Vogelbaum MA, Chang S, Wen PY, Soffietti R.

Neuro Oncol. 2019 May 6;21(5):571-584. doi: 10.1093/neuonc/noz012.

34.

Imaging and diagnostic advances for intracranial meningiomas.

Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougère C, Schmidt NO, Tonn JC, Vogelbaum MA, Wen PY, Aldape K, Nassiri F, Zadeh G, Dunn IF; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i44-i61. doi: 10.1093/neuonc/noy143.

35.

Molecular and translational advances in meningiomas.

Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, Perry A, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i4-i17. doi: 10.1093/neuonc/noy178.

36.

Advances in multidisciplinary therapy for meningiomas.

Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i18-i31. doi: 10.1093/neuonc/noy136.

37.

The lomustine crisis: awareness and impact of the 1500% price hike.

Taylor JW, Armstrong T, Kim AH, Venere M, Acquaye A, Schrag D, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):1-3. doi: 10.1093/neuonc/noy189. No abstract available.

38.

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA.

Nature. 2019 Jan;565(7738):234-239. doi: 10.1038/s41586-018-0792-9. Epub 2018 Dec 19.

39.

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.

Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE.

Clin Cancer Res. 2019 Apr 1;25(7):2305-2313. doi: 10.1158/1078-0432.CCR-18-2572. Epub 2018 Dec 17.

PMID:
30559168
40.

Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.

Dworkin M, Mehan W, Niemierko A, Kamran SC, Lamba N, Dietrich J, Martinez-Lage M, Oh KS, Batchelor TT, Wen PY, Loeffler JS, Shih HA.

J Neurooncol. 2019 Mar;142(1):69-77. doi: 10.1007/s11060-018-03063-1. Epub 2018 Nov 28.

PMID:
30488294
41.

Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.

George E, Kijewski MF, Dubey S, Belanger AP, Reardon DA, Wen PY, Kesari S, Horky L, Park MA, Huang RY.

AJR Am J Roentgenol. 2018 Dec;211(6):1342-1347. doi: 10.2214/AJR.18.19988. Epub 2018 Oct 17.

PMID:
30332289
42.

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G.

Neuro Oncol. 2019 Feb 14;21(2):167-178. doi: 10.1093/neuonc/noy132.

PMID:
30189035
43.

PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.

Kurz SC, Cabrera LP, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee EQ, Reardon DA, Wen PY.

Neurology. 2018 Oct 2;91(14):e1355-e1359. doi: 10.1212/WNL.0000000000006283. Epub 2018 Aug 31.

PMID:
30171077
44.

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137.

45.

Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression.

Huang RY, Unadkat P, Bi WL, George E, Preusser M, McCracken JD, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, Weller M, Raizer JJ, Schiff D, Wen PY.

Neuro Oncol. 2019 Feb 14;21(2):234-241. doi: 10.1093/neuonc/noy126.

PMID:
30085283
46.

The Interface Between Neurology and Oncology.

Lee EQ, Wen PY.

Neurol Clin. 2018 Aug;36(3):xiii-xiv. doi: 10.1016/j.ncl.2018.05.001. Epub 2018 Jun 13. No abstract available.

PMID:
30072077
47.

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.

Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R.

Neurology. 2018 Aug 28;91(9):403-413. doi: 10.1212/WNL.0000000000006083. Epub 2018 Jul 27. Review.

48.

Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?

Lee EQ, McFaline-Figueroa JR, Cloughesy TF, Wen PY.

Neuro Oncol. 2018 Jul 5;20(8):1144. doi: 10.1093/neuonc/noy092. No abstract available.

49.

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.

Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY.

Clin Cancer Res. 2018 Oct 1;24(19):4643-4649. doi: 10.1158/1078-0432.CCR-18-1025. Epub 2018 Jun 25.

50.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056. Review.

Supplemental Content

Support Center